Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries
On January 1, 2006, Medicare Part D prescription drug coverage was initiated. Concern was immediately voiced by the American Association of Retired Persons (AARP) and Families USA that, in response to this program, the pharmaceutical industry may raise prices for drugs most often used by the elderly...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Springer Science + Business Media B. V
2009
|
| In: |
Journal of business ethics
Year: 2009, Volume: 84, Issue: 1, Pages: 75-88 |
| Further subjects: | B
Ethics
B pricing strategy B Access B Diffusion |
| Online Access: |
Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1785632647 | ||
| 003 | DE-627 | ||
| 005 | 20230427062126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220112s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10551-008-9682-7 |2 doi | |
| 035 | |a (DE-627)1785632647 | ||
| 035 | |a (DE-599)KXP1785632647 | ||
| 035 | |a (DE-He213)s10551-008-9682-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Balotsky, Edward R. |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a On January 1, 2006, Medicare Part D prescription drug coverage was initiated. Concern was immediately voiced by the American Association of Retired Persons (AARP) and Families USA that, in response to this program, the pharmaceutical industry may raise prices for drugs most often used by the elderly. This article examines the ethical implications of a revenue-maximizing pricing strategy in an industry in which third party financing mitigates an end product’s true cost to the user. The perspectives of three stakeholder groups are examined: the elderly, as consumers of prescription drugs, the pharmaceutical industry, as product manufacturer and beneficiary of derived profits, and the total U.S. population, as the ultimate payer for the program via tax revenues. Key questions explored include the relationships among price strategy and access to drugs at both the micro (Medicare cohort) and macro (total population) levels, and on drug development or enhancement. The role of profit in a capitalism-based health care system is also examined. Hospital industry impact on these same stakeholder groups in response to the original 1965 Medicare law is used to compare and contrast possible outcomes of the new drug program. It is predicted that pharmaceutical firms will mimic the hospital industry, adopting a price maximizing strategy for drugs covered by the program. In the process, a utilitarian effect occurs: the benefits of increased access and diffusion of drugs counterbalance inequities in financing Medicare Part D. | ||
| 601 | |a Strategie | ||
| 601 | |a Industrie | ||
| 650 | 4 | |a pricing strategy | |
| 650 | 4 | |a Ethics | |
| 650 | 4 | |a Diffusion | |
| 650 | 4 | |a Access | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of business ethics |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1982 |g 84(2009), 1, Seite 75-88 |h Online-Ressource |w (DE-627)270937129 |w (DE-600)1478688-6 |w (DE-576)121465284 |x 1573-0697 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2009 |g number:1 |g pages:75-88 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10551-008-9682-7 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 84 |j 2009 |e 1 |h 75-88 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4033691529 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1785632647 | ||
| LOK | |0 005 20220112043655 | ||
| LOK | |0 008 220112||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2021-12-30#1253103B707325069637BAA7E6747A20F494EA88 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||
| STA | 0 | 0 | |a Diffusion,Diffusion |
| STB | 0 | 0 | |a Diffusion,Diffusion (physique) |
| STC | 0 | 0 | |a Difusión,Difusión |
| STD | 0 | 0 | |a Diffusione |
| STG | 0 | 0 | |a Difusão |
| STH | 0 | 0 | |a Диффузия (экономика) |
| STI | 0 | 0 | |a Διάχυση <οικονομία>,Diffusion (οικονομία) |
| SYE | 0 | 0 | |a Diffusionsprozess |